- Home
- PAVM vs SRTS Comparison
PAVM vs SRTS Comparison
Compare PAVM & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | SRTS |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 48.9M |
| IPO Year | 2015 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PAVM | SRTS |
|---|---|---|
| Price | $4.92 | $3.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $65.00 | $7.00 |
| AVG Volume (30 Days) | ★ 32.2K | 27.0K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,000,000.00 | ★ $27,482,000.00 |
| Revenue This Year | $603.94 | $2.00 |
| Revenue Next Year | $33.16 | $34.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.00 | N/A |
| 52 Week Low | $0.21 | $2.66 |
| 52 Week High | $28.44 | $5.49 |
Technical Indicators
Market Signals| Indicator | PAVM | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 48.86 | 57.58 |
| Support Level | $4.23 | $2.80 |
| Resistance Level | $6.56 | $3.70 |
| Average True Range (ATR) | 0.42 | 0.20 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 62.86 | 71.43 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.